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Abstract
Background: The long-term prognosis after cognitive behavioral therapy (CBT) in outpatient groups for panic
disorder and agoraphobia is not well known. The purpose of this study was to assess long-term outcomes in terms
of psychological health, health-related quality of life (HRQoL), quality of life (QoL) and treatment satisfaction after
CBT for panic disorder and agoraphobia.
Methods: The sample consisted of 68 patients (61% response rate), who were assessed at pretreatment; at the start
and end of treatment; and after 3 months, after 1 year, and over the long term (M = 24 years; SD = 5.3; range: 12 to
31 years). The main outcome was the total score on the Phobic Avoidance Rating Scale (PARS-total). At long-term
follow-up, HRQoL was measured with the RAND-12 questionnaire, and QoL was measured with two questions from
the “Study on European Union Statistics on Income and Living Conditions”. Patient experiences and treatment
satisfaction were assessed by the Generic Short Patient Experiences Questionnaire. A marginal longitudinal model
was applied to study the main outcome.
Results: The effect size of the long-term change (mean change/ pooled SD) in the PARS-total score was (− 1.6, p < 0.001)
and was stable over time. A PARS-total score reduction of 50% was found in 98% of patients at the long-term follow-up.
The patients’ HRQoL and QoL were similar to the expected scores for the general Norwegian population. Of the patients,
95% reported high to very high satisfaction with the CBT, and 93% reported large treatment benefits.
Conclusions: To the best of our knowledge, this study has the longest follow-up after group CBT for panic disorder and
agoraphobia, showing a good prognosis in ≥93% of the participating patients.
Keywords: Anxiety, Panic disorder, Agoraphobia, CBT, Group therapy, Long term follow-up, Quality of life, Treatment
satisfaction
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Background
Panic disorder and agoraphobia are disabling disorders
often associated with impairments in a wide range of life
areas [1]. The first documented treatment for agorapho-
bia was exposure therapy, and later, the cognitive ele-
ments of treatment were developed. The combined form
of treatment including both exposure and cognitive ther-
apy was labeled cognitive behavioral therapy (CBT),
which is increasingly viewed as the treatment of choice
[2]. Antidepressant medication use is well documented
[3], and there is also empirical evidence for less trad-
itional forms of treatment, such as physical exercise [4].
Several randomized controlled trials have shown good
effects of CBT in the treatment of panic disorder with or
without agoraphobia [2, 5]. In the majority of these stud-
ies, patients were selected with strict exclusion criteria,
and therapists received specialized training. Fewer stud-
ies have been conducted in the general clinical setting,
where patients have been treated by therapists without
specialized therapeutic competence. CBT is most often
delivered individually, and most scientific studies have
addressed individual CBT. Some have found that good
results can also be achieved following group CBT [6],
and this format may be more cost effective and feasible
in the clinical setting. Nevertheless, the number of stud-
ies, especially long-term studies (> 2 years), on CBT in
groups is scarce [5, 7–14]. Long term outcome following
CBT varies across studies. The first studies showed
modest results, indicating that these disorders tend to
follow a chronic course [9–12]. In two long-term studies
with patients following inpatient treatment with em-
phasis of group therapy, 38 patients (71%) were assessed
20 years after a combination of exposure and psycho-
dynamic therapy [13], while 31 (67%) were investigated
after cognitive and guided mastery therapy [14]. The
long-term outcomes were very good in both samples.
We found no long-term follow-up study of patients
treated with group CBT in the general clinical setting.
Moreover, a Cochrane review recommended that studies
in this field include broader measures of quality of life
(QoL) in addition to standard disease-specific outcomes
[8]. Thus, we wanted to address these research needs by
extending a prior study (N = 83) published in 1998 [15].
In that study, group CBT was offered to patients with
panic disorder belonging to the catchment area of the
outpatient clinic of the Central Hospital of Førde in
Western Norway, with a rural population of 35,000
people. In general, the patients improved during treat-
ment and maintained those gains at one-year follow-up.
The principal aim of the current study was to investi-
gate the long-term trajectories of outcomes in panic dis-
order following outpatient CBT in groups in a general
clinical setting by extending the 1998 sample and per-
forming a long-term follow-up. The secondary aims
were to investigate these patients’ long-term health-
related quality of life (HRQoL) and QoL compared to
those of the average general Norwegian population and to
address patient experiences and treatment satisfaction.
Methods
In this prospective naturalistic study, assessments were
carried out by personal interviews at pretreatment, at
the first and last treatment sessions, and at the 3-month,
1-year, and 12 to 31 years follow-up (mean follow-up
time was 24-years; SD 5.3). The wide range of long-term
follow-up time points is due to the merging of the sam-
ple from the 1998 study and new patients. The study
was approved by the Regional Committee for Medical
Research Ethics in Western Norway (REK) and is regis-
tered in the REK archive (reference number: 2016/2693)
[16]. Patients were recruited from a regional outpatient
clinic serving a catchment area of approximately 35,000
people referred from doctors in primary care or somatic
departments. The treatment team received all referrals
with a probable diagnosis of panic disorder. Those who
met the DSM-III-R criteria for panic disorder with or
without agoraphobia and did not meet the criteria for
psychotic or posttraumatic stress disorders were offered
CBT in a group format.
Sample
Of the 183 eligible patients who received treatment in
the period 1989–2008, we were not able to trace the ad-
dresses of 63 patients (34%), while 8 (5%) were deceased.
Thus, we invited 112 patients to participate. Of these, 2
(1%) did not want to participate, 9 (5%) wanted to par-
ticipate but were unable for different reasons, and 32
(17%) did not respond. The final sample consisted of 68
patients, yielding a response rate of 61%, and they met
with the therapists at the hospital. The average follow-
up time since treatment was 23.8 years (SD, 5.4), ranging
from 12 to 31 years. The participant characteristics at
the start of treatment are presented in Table 1.
Treatment program
Treatment was delivered in groups of 6 to 10 partici-
pants. The groups met each week for 11 four-hour ses-
sions. The families or significant others were invited to
one of the sessions. All group sessions were conducted
by the same social worker (TO) assisted by various ther-
apists who were either registered psychiatric nurses or
registrars (TB and others). The patients in each group
had two lectures on anxiety disorders and their treat-
ment by EWM, who also supervised the therapists
weekly. At the pretreatment stage, the patients were
given a brief outline of the treatment explaining the ra-
tionale for exposure and cognitive restructuring. All pa-
tients who met the criteria for major depression during
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the pretreatment visit were offered antidepressants. Ben-
zodiazepines were tapered and stopped within the first
weeks of treatment. Patients were encouraged not to use
alcohol while in therapy.
Initial sessions were devoted to psychoeducation with
special emphasis on the connections between perceived
threat, somatic symptoms of arousal, automatic thoughts,
and anxious feelings. The physiological symptoms of sym-
pathetic activation were examined in detail, as were feelings
of disaster and catastrophic interpretations of somatic
symptoms. The patients were assisted in identifying their
own vicious cycles of symptoms, thoughts, and feelings and
learned to rate their anxiety on a 0–10 scale. The patients
were repeatedly encouraged to use diaries for recording
anxiety ratings, noting daily homework assignments, dis-
cussing dysfunctional thoughts, and personally monitoring
the gains made in therapy [17].
All participants underwent voluntary hyperventilation
early in treatment. Behavioural experiments were used
to some extent.
The positive benefits of regular physical activity were
emphasized, and the ways in which physical activity in-
fluences health in general and anxiety specifically were
explained. The patients were encouraged to implement a
life-long habit of walking at least 30 min daily or under-
taking other physical activities of their choice.
Group sessions consisted of four modules
1. Review of homework, including anxiety ratings
during exposure, and discussion of somatic
symptoms, dysfunctional thoughts, and coping
strategies.
2. Planning, performing, and reviewing the present
day’s individual in vivo exposure at downtown
locations, such as attending public offices, riding
the omnibus, shopping, walking the streets, or
going to a café.
3. Review of the progress made during the exposure
and recapitulation of cognitive theory.
4. Assignment of daily homework for the week to
come
Procedure
For the long-term follow-up investigation patients met
in groups and were offered sandwiches, tea or coffee.
Travel expenses were covered. The Phobic Avoidance
Rating Scale (PARS) was scored in individual interviews.
The other instruments were self-rating and filled in by
the patients while sitting in the group.
Measures
The main outcome is based on the Phobic Avoidance
Rating Scale (PARS), an observer-rated scale that mea-
sures the degree of avoidance. Each item is scored on a
5-point scale where 0 represents no avoidance and 4 in-
dicates total avoidance of the situation in question [18].
We defined a 50% reduction in the PARS-total score as
the primary indicator of a substantial response to treat-
ment. Reduced avoidance of this magnitude is readily
recognized as clinically significant by both the patient
and therapist.
Table 1 Pretreatment patient characteristics
Characteristics Long-term participants (n = 68) Non-long-term participants (n = 114)
Age, years, mean (SD) 34.8 (10.3) 37.6 (10.0)
Females, % 73.5 69.1
Marital status,%





Receiving social security benefits 13.5 18.5
Other, not employed 17.7 17.5
Age at onset of anxiety disorder, mean (SD) 28.0 (9.0) 30.6 (10.4)
Years of duration of anxiety disorder, mean (SD) 6.8 (7.4) 6.8 (8.0)
Previous psychiatric treatment, % 48.5 51.8
DSM-III-R Axis diagnosis, Panic disorder, %
With agoraphobia 77.9 78.1
Without Agoraphobia 22.1 21.9
SD standard deviation
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Level of depression was assessed by the Beck Depres-
sion Inventory (BDI) [19], the degree of catastrophic in-
terpretations of somatic symptoms by the Body
Sensations Questionnaire (BSQ) [20], the fear of fear by
the Agoraphobic Cognitions Questionnaire (ACQ) [20]
and Agoraphobic Cognitions Scale (ACS) [21], and the
degree of phobic avoidance by the Mobility Inventory
for Agoraphobia (MIA) [22], with subscales for avoid-
ance both alone and accompanied by others.
HRQoL, a multidimensional construct encompassing
physical, psychological and social dimensions of health
[23], was measured with the RAND-12 questionnaire,
which covers 12 dimensions of functioning and well-
being [24]. The RAND-12 has two summary scores: the
physical component summary (PCS) and mental compo-
nent summary (MCS). To calculate the summary scores,
we applied a formula allowing the PCS and MCS to be
freely correlated [24]. Higher PCS and MCS represent
better scores. RAND-12 scores from the general popula-
tion were obtained from the Norwegian Survey on Liv-
ing Conditions in 2002 (N = 5396) [25].
QoL, a global construct encompassing an overall as-
sessment of well-being or life satisfaction [23], was
assessed by two questions: (1) Life satisfaction: “Overall,
how satisfied are you with your life nowadays (where
zero is not at all satisfied and 10 is completely satis-
fied)?” (2) Life meaning: “Overall, to what extent do you
feel that the things you do in your life are worthwhile
(where zero is not at all worthwhile and 10 is completely
worthwhile)?” QoL scores from the general population
were obtained from the Norwegian part of the European
Union Statistics on Income and Living Conditions (EU-
SILC) Survey in 2017 (N = 6168) [25].
Patient experiences and treatment satisfaction were
assessed by the Generic Short Patient Experiences Ques-
tionnaire (GS-PEQ), which consists of ten generic core
questions that cover the essential dimensions of users’
experiences with a range of specialist health care services
[26]. The ten GS-PEQ item scores are intended to be
used as single indicators for each of the ten specific con-
tent areas.
HRQoL, QoL and patient experiences were assessed
only at long-term follow-up.
Statistics
Data are presented as frequencies or percentages and as
means and standard deviations or 95% confidence inter-
vals. Exact two-sided p-values are reported. Longitudinal
marginal models with an unstructured covariance struc-
ture were used in analyses of change, with time as a
fixed categorical effect. This method handles missing y-
data by estimating outcomes based on all available data.
The length of time since starting treatment was not cor-
related with long-term PARS-total scores (r = 0.06, p =
0.642). Thus, we coded all long-term data (ranging from
12 to 31 years) into one category. The trajectories of the
PARS-total score during the first year of follow-up for
long-term participants versus non-long-term participants
were displayed, and the interaction effect of time*group
was tested. Age- and gender-adjusted comparisons of gen-
eric health status and QoL between the patient group and
the general population were conducted with a one-sample
t-test. Effect sizes of changes over time were calculated by
using change scores from the longitudinal marginal
models divided by the crude pooled standard deviations at
the start of treatment and at the last time point. Effect
sizes for score differences in the patient group compared
to the general population were calculated by using differ-
ence scores divided by the standard deviations in the pa-
tient group. Effect sizes were interpreted according to the
following criteria: trivial (< 0.2), small (0.2 to < 0.5), mod-
erate (0.5 to < 0.8 SD), and large (≥0.8) [27]. The statistical
analyses were conducted using SPSS, version 25.0 (SPSS
Inc., Chicago, USA).
Results
The PARS score was stable from pretreatment to the
start of treatment. The PARS-total score improved dur-
ing treatment (p < 0.001) (Table 2). The effect size was
large at the end of treatment and remained stable there-
after. A reduction of 50% in the PARS-total score was
found in 82% of the patients by the end of treatment
and in 98% of patients by the 24-year follow-up. All sec-
ondary outcomes also improved over time (Table 2; p <
0.001 for all). The standard deviations for all scores de-
creased over time, indicating that the response to treat-
ment was general. There were no significant differences
between the patients who were assessed at the 24-year
follow-up and the other patients in terms of their PARS-
total trajectories over time (p = 0.647) (Fig. 1).
The patients’ HRQoL and QoL 24 years after CBT
were similar to the expected scores in the general popu-
lation after adjustment for age and gender (Table 3). De-
tails on patient experiences and treatment satisfaction at
the 24-year follow-up are presented in Table 4. The pa-
tients had high ratings on all items, with 95% reporting
high to very high satisfaction with the CBT and 93%
reporting large benefits.
Discussion
To the best of our knowledge, this study has the longest
follow-up after group CBT for panic disorder and agora-
phobia. The effect size for clinical treatment was large at
the end of treatment and remained stable thereafter. A
50% reduction in the PARS-total score was found in 98%
of patients at the long-term follow-up, and 93% of pa-
tients were satisfied with the outcomes. The patients’
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HRQoL and QoL were similar to the expected scores for
the general Norwegian population.
Our results correspond well with previous shorter-
term studies on the treatment of panic disorder and
agoraphobia [2, 4]. The few studies reporting long-term
outcomes have diverging results, and the explanations
for this is not clear. Our results correspond best to the
previous studies with longest follow-up [13, 14]. An in-
teresting common feature of these studies is the focus
on the group format. Our clinical experience indicate
that the group fellowship was important for many pa-
tients. Systematic exposure treatment and cognitive ther-
apy seem to yield substantial and lasting therapeutic
gains, and these results can also be achieved in the
general clinical setting. Thus, the good results following
individual CBT seem to be achieved by group CBT as
well. This format is suitable for training new therapists,
who can learn the method by working as co-therapists
with more experienced professionals.
The main strength of this study is its length of follow-
up. Moreover, the study was conducted in the general
clinical setting, had few exclusion criteria and included
participants with multiple comorbidities. Thus, the re-
sults are generalizable to the general clinical setting. Fur-
thermore, we had a broad set of validated measures
encapsulating mental health, HRQoL, QoL, and patient
experiences and treatment satisfaction. The study’s main
limitations are its observational design, and we do not















PARS-tot. 1.5 (0.9) 1.5 (0.9) 0.4 (0.5) 0.4 (0.7) 0.4 (0.7) 0.3 (0.5) −1.6
PARS-sep. 1.6 (1.0) 1.5 (1.0) 0.4 (0.5) 0.3 (0.6) 0.4 (0.7) 0.3 (0.5) −1.6
PARS-soc. 1.5 (1.1) 1.5 (1.1) 0.4 (0.7) 0.5 (0.8) 0.5 (0.8) 0.3 (0.5) −1.4
MI-AAC 50.5 (20.1) 50.6 (19.3) 34.4 (11.0) 33.7 (10.8) 33.3 (13.1) 31.4 (7.2) −1.3
MI-AAL 69.2 (25.0) 67.8 (27.2) 42.3 (15.8) 41.2 (15.6) 40.5 (19.4) 37.5 (14.5) −1.6
ACQ 37.0 (10.1) 37.8 (11.1) 25.9 (9.0) 24.1 (9.0) 22.9 (7.6) 21.8 (7.7) −1.7
BSQ 47.3 (13.6) 46.6 (12.4) 29.9 (10.5) 28.9 (11.1) 28.4 (12.2) 28.2 (11.5) −1.5
BDI 16.7 (8.2) 15.5 (8.6) 7.4 (6.8) 7.3 (8.1) 6.5 (8.1) 5.9 (5.9) −1.5
Long-term follow-up (mean = 24 years; range = 12–31 years)
Abbreviations: ACQ Anxiety Cognitions Questionnaire, ACS Agoraphobic Cognitions Scale, BDI Beck Depression Inventory, BSQ Body Sensation Questionnaire, MI-
ACC Mobility Inventory for Agoraphobia, Avoidance Accompanied, MI-ALL Mobility Inventory for Agoraphobia, Avoidance Alone, PARS Phobic Avoidance Rating
Scale, PARS-sep PARS Separation Subscale, PARS-soc PARS Social Subscale
P-values were < 0.001 for the effect of time on all scales
a Effect size: (Long-term follow-up – Pretreatment / pooled standard deviation)
Fig. 1 Mean total Phobic Avoidance Rating Scale trajectories over time in patients attending the 24-year follow-up (long-term participants) versus
the other patients (non-long-term participants). Pre: pretreatment, Start: start of treatment, End: end of treatment, 3-mo: 3-month follow-up, 1 y:
1-year follow-up, 24 y: mean follow up time = 24-years, range 12–31 years. P-value for time * group interaction = 0.647
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know the long-term prognosis of the 39% of patients
who did not participate in the long-term follow-up. Loss
of patients is also observed in other studies with a very
long follow-up period [13, 14]. Patients may have chosen
not to participate in the long-term follow-up because
they were doing well and perceived their attendance as
unnecessary, because they were doing poorly and did
not want further contact, or because they had other rea-
sons unrelated to the study outcomes. However, it is re-
assuring that the PARS-total trajectories during the first
year after treatment were similar in long-term -and
other participants. Unfortunately, we have no measure
of remission, only of responders. It would also had been
nice to have a therapist rating which covered panic/
agoraphobia in a broader sense than only avoidance, but
these other aspects are covered by self- report
instruments.
Conclusions
Our study suggests that CBT in groups is feasible and
that the therapeutic gains last for a very long period of
time. This finding is good news for a common mental
health problem. However, further studies are needed to
establish a robust body of evidence on this matter.
Table 3 General health status and quality of life in the patient group at 12 to 31-years follow-up compared to the general
Norwegian population
Outcomes Patient mean (SD) General population mean P-value Effect size
Physical health status 49.5 (9.4) 49.4 0.923 0.1
Mental health status 48.8 (11.4) 51.1 0.104 −0.3
Life satisfaction 8.0 (2.1) 8.1 0.699 −0.1
Life meaning 8.3 (1.7) 8.1 0.413 0.2
Differences in outcomes are adjusted for age and gender. Effect size =mean difference in scores between patients and the general population divided by the
standard deviation of the patient scores
Table 4 The Generic Short Patient Experiences Questionnaire scores at 12 to 31-years follow-up










Did the clinicians talk to you in a way that was
easy to understand?
0 0 1 26 31 0
Do you have confidence in the clinicians’
professional competence?
0 0 1 14 43 0
Did you get sufficient information about your
diagnosis/your afflictions?
0 0 5 26 27 0
Did you perceive the treatment you received
as suited to your situation?
0 0 4 21 33 0
Were you involved in any decisions regarding
your treatment?
0 2 6 21 28 1
Did you perceive the institution’s work as well
organized?
0 0 1 24 31 2
Do you believe that you were in any way given
the wrong treatment (according to your own
judgment)?
49 4 1 1 0 3
Overall, were the help and treatment you received
at the institution satisfactory?
1 0 1 17 36 1








Did you have to wait before you were admitted
for services at the institution?
27 25 3 1 0
No benefit Small benefit Some benefit Great benefit Huge benefit Not applicable
Overall, what benefit have you had from the
care at the institution?
0 1 3 20 33 0
The results are presented as the distribution in scores according to the crude numbers of patients on the different answer categories (number of patients ranging
from 56 to 58)
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